98 related articles for article (PubMed ID: 20034901)
21. CD4+CD25+ regulatory T cells in the peripheral blood of patients with breast cancer and non-small cell lung cancer.
Okita R; Saeki T; Takashima S; Yamaguchi Y; Toge T
Oncol Rep; 2005 Nov; 14(5):1269-73. PubMed ID: 16211295
[TBL] [Abstract][Full Text] [Related]
22. Expression of Foxp3 in non-small cell lung cancer patients is significantly higher in tumor tissues than in normal tissues, especially in tumors smaller than 30 mm.
Ishibashi Y; Tanaka S; Tajima K; Yoshida T; Kuwano H
Oncol Rep; 2006 May; 15(5):1315-9. PubMed ID: 16596204
[TBL] [Abstract][Full Text] [Related]
23. Reciprocal CD4+ T-cell balance of effector CD62Llow CD4+ and CD62LhighCD25+ CD4+ regulatory T cells in small cell lung cancer reflects disease stage.
Koyama K; Kagamu H; Miura S; Hiura T; Miyabayashi T; Itoh R; Kuriyama H; Tanaka H; Tanaka J; Yoshizawa H; Nakata K; Gejyo F
Clin Cancer Res; 2008 Nov; 14(21):6770-9. PubMed ID: 18980970
[TBL] [Abstract][Full Text] [Related]
24. Clinical significance of expanded Foxp3⁺ Helios⁻ regulatory T cells in patients with non-small cell lung cancer.
Muto S; Owada Y; Inoue T; Watanabe Y; Yamaura T; Fukuhara M; Okabe N; Matsumura Y; Hasegawa T; Osugi J; Hoshino M; Higuchi M; Suzuki H; Gotoh M
Int J Oncol; 2015 Dec; 47(6):2082-90. PubMed ID: 26460798
[TBL] [Abstract][Full Text] [Related]
25. Tumor infiltrating lymphocytes and macrophages have a potential dual role in lung cancer by supporting both host-defense and tumor progression.
Kataki A; Scheid P; Piet M; Marie B; Martinet N; Martinet Y; Vignaud JM
J Lab Clin Med; 2002 Nov; 140(5):320-8. PubMed ID: 12434133
[TBL] [Abstract][Full Text] [Related]
26. Carcinoembryonic antigen level in serum and pleural lavage fluid in non-small cell lung cancer.
Tomita M; Shimizu T; Ayabe T; Yonei A; Onitsuka T
Thorac Cardiovasc Surg; 2010 Sep; 58(6):350-3. PubMed ID: 20824588
[TBL] [Abstract][Full Text] [Related]
27. Generation of cytotoxic T lymphocytes against autologous lung cancer cells resistant to apoptosis.
Hiraki A; Ono T; Tanaka M; Kiura K; Ueoka H; Kawai H; Harada M; Nakayama E; Noguchi Y
Anticancer Res; 2001; 21(4A):2561-7. PubMed ID: 11724322
[TBL] [Abstract][Full Text] [Related]
28. Lung tissue and tumour-infiltrating T lymphocytes in patients with non-small cell lung carcinoma and chronic obstructive pulmonary disease (COPD): moderate/severe versus mild stage of COPD.
Marc MM; Korosec P; Kern I; Sok M; Ihan A; Kosnik M
Scand J Immunol; 2007 Dec; 66(6):694-702. PubMed ID: 17949407
[TBL] [Abstract][Full Text] [Related]
29. Foxp3 expressing CD4+ CD25+ and CD8+CD28- T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma.
Meloni F; Morosini M; Solari N; Passadore I; Nascimbene C; Novo M; Ferrari M; Cosentino M; Marino F; Pozzi E; Fietta AM
Hum Immunol; 2006; 67(1-2):1-12. PubMed ID: 16698419
[TBL] [Abstract][Full Text] [Related]
30. [Clinical significance of PCNA expression in non-small cell lung cancer].
Dworakowska D
Pneumonol Alergol Pol; 2005; 73(3):292-6. PubMed ID: 16989169
[No Abstract] [Full Text] [Related]
31. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression.
Konishi J; Yamazaki K; Azuma M; Kinoshita I; Dosaka-Akita H; Nishimura M
Clin Cancer Res; 2004 Aug; 10(15):5094-100. PubMed ID: 15297412
[TBL] [Abstract][Full Text] [Related]
32. Clinical significance of insulin receptor substrate-I down-regulation in non-small cell lung cancer.
Han CH; Cho JY; Moon JT; Kim HJ; Kim SK; Shin DH; Chang J; Ahn CM; Kim SK; Chang YS
Oncol Rep; 2006 Dec; 16(6):1205-10. PubMed ID: 17089038
[TBL] [Abstract][Full Text] [Related]
33. The prognostic value of intraepithelial and stromal CD3-, CD117- and CD138-positive cells in non-small cell lung carcinoma.
Al-Shibli K; Al-Saad S; Andersen S; Donnem T; Bremnes RM; Busund LT
APMIS; 2010 May; 118(5):371-82. PubMed ID: 20477813
[TBL] [Abstract][Full Text] [Related]
34. A different pattern of cytotoxic T lymphocyte recognition against primary and metastatic tumor cells in a patient with nonsmall cell lung carcinoma.
So T; Takenoyama M; Ichiki Y; Mizukami M; So T; Hanagiri T; Sugio K; Yasumoto K
Cancer; 2005 Jan; 103(1):200-8. PubMed ID: 15573370
[TBL] [Abstract][Full Text] [Related]
35. CD4+ CD25high regulatory T cells reduce T cell transendothelial migration in cancer patients.
Enarsson K; Lundin BS; Johnsson E; Brezicka T; Quiding-Järbrink M
Eur J Immunol; 2007 Jan; 37(1):282-91. PubMed ID: 17163448
[TBL] [Abstract][Full Text] [Related]
36. Reciprocal functional modulation of the activation of T lymphocytes and fibroblasts derived from human solid tumors.
Barnas JL; Simpson-Abelson MR; Brooks SP; Kelleher RJ; Bankert RB
J Immunol; 2010 Sep; 185(5):2681-92. PubMed ID: 20686130
[TBL] [Abstract][Full Text] [Related]
37. Anti-survivin antibody responses in lung cancer.
Karanikas V; Khalil S; Kerenidi T; Gourgoulianis KI; Germenis AE
Cancer Lett; 2009 Sep; 282(2):159-66. PubMed ID: 19380192
[TBL] [Abstract][Full Text] [Related]
38. Autologous dendritic cell vaccines for non-small-cell lung cancer.
Hirschowitz EA; Foody T; Kryscio R; Dickson L; Sturgill J; Yannelli J
J Clin Oncol; 2004 Jul; 22(14):2808-15. PubMed ID: 15254048
[TBL] [Abstract][Full Text] [Related]
39. Lymphocyte subsets in lung cancer.
Wesselius LJ; Wheaton DL; Manahan-Wahl LJ; Sherard SL; Taylor SA; Abdou NA
Chest; 1987 May; 91(5):725-9. PubMed ID: 3032522
[TBL] [Abstract][Full Text] [Related]
40. An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer.
Meyer RG; Korn S; Micke P; Becker K; Huber C; Wölfel T; Buhl R
Lung Cancer; 2007 Oct; 58(1):88-94. PubMed ID: 17599645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
